

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/16604 A1

(51) International Patent Classification⁷: **G01N 33/68**,
C12Q 1/25, G01N 33/50, 33/566

(21) International Application Number: **PCT/US00/23729**

(22) International Filing Date: **29 August 2000 (29.08.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
09/385,918 30 August 1999 (30.08.1999) **US**

(71) Applicant (for all designated States except US): **SIGNAL PHARMACEUTICALS, INC.** [US/US]; 5555 Oberlin Drive, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HOEKSTRA, Merl, F.** [US/US]; 2361 Manchester Avenue, Cardiff-by-the-sea,

CA 92007 (US). **XIE, Weilin** [US/US]; 5375 Ruelle de Mer, San Diego, CA 92130 (US). **MURRAY, Brion, W.** [US/US]; 2685 Narcissus Drive, San Diego, CA 92106 (US). **MERCURIO, Frank, M.** [US/US]; 2707 Caminito Verdugo, Del Mar, CA 92014 (US).


(74) Agents: **BAYNHAM, Robert, J. et al.**; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: **SCREENING FOR AGENTS MODULATING TGF-BETA CELL SIGNALING**



(57) Abstract: Methods are provided for identifying agents that modulate signaling mediated by transforming growth factor beta (TGF-β) and members of the TGF-β family, such as bone morphogenic protein (BMP). Such agents may be identified using screens that evaluate candidate agents for the ability to modulate Smad protein degradation. Agents identified as described herein may be used to augment or inhibit signaling mediated by one or more TGF-β family members in a variety of cell types and for therapeutic purposes.

Best Available Copy

WO 01/16604 A1



IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *With international search report.*
- *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

SCREENING FOR AGENTS MODULATING TGF-BETA CELL SIGNALING

TECHNICAL FIELD

The present invention relates generally to methods for identifying agents that modulate signaling mediated by transforming growth factor beta (TGF- β) and members of the TGF- β family, such as bone morphogenic protein (BMP). The invention is more particularly related to screens for use in evaluating agents for the ability to modulate Smad protein degradation, and to methods using such agents to augment or inhibit BMP-mediated signaling in a variety of cell types.

BACKGROUND OF THE INVENTION

The transforming growth factor beta (TGF- β) superfamily is a large family of multifunctional proteins that regulate a variety of cellular functions, including cellular proliferation, migration, differentiation and apoptosis. TGF- β , the founding member of TGF- β family, has been shown to play a variety of roles ranging from embryonic pattern formation to cell growth regulation in adult tissues. TGF- β exerts its biological functions by signal transduction cascades that ultimately activate and/or suppress expression of a set of specific genes. Other TGF-beta family members include activins, inhibins and Bone Morphogenic Proteins (BMPs). BMP-mediated signal transduction is important for a variety of normal processes, including bone growth and the function of the nervous system, eyes and organs such as kidneys.

TGF- β family members generally initiate signal transduction by first binding to a receptor. TGF- β , for example, triggers its signal by first binding to its type II receptor, then recruiting and activating its type I receptors. The activated type I receptors then phosphorylate its intracellular signal transducer molecules, the Smad proteins (Heldin et al., *Nature* 390:465-471, 1997; Derynck et al., *Cell* 95:737-740, 1998). Similarly, BMP binds to a BMP serine/threonine transmembrane receptor protein kinases. The signals are further transduced from the receptors to the nuclei, resulting in altered patterns of gene expression. Signal transduction from BMP receptor

to nuclei is known to involve Smad family proteins, certain of which become incorporated into transcriptional complexes and activate downstream genes.

Smads are receptor-activated, signal transducing transcription factors that transmit signals from TGF- β family receptors. Members of the Smad family of proteins have been identified based on homology to the *Drosophila* gene Mothers against dpp (mad), which encodes an essential element in the *Drosophila* dpp signal transduction pathway (see Sekelsky et al., *Genetics* 139:1347-1358, 1995; Newfeld et al., *Development* 122:2099-2108, 1996). Smad proteins are generally characterized by highly conserved amino- and carboxy-terminal domains separated by a proline-rich linker. The amino terminal domain (the MH1 domain) mediates DNA binding, and the carboxy terminal domain (the MH2 domain) associates with the receptor.

To date, eight Smad proteins have been identified and shown to participate in signal responses induced by TGF- β family members (see Kretzschmar and Massague, *Current Opinion in Genetics and Development* 8:103-111, 1998). These Smads can be divided into three subgroups. One group (Smad1, 2, 3, 5 and 8) includes Smads that are direct substrates of a TGF- β family receptor kinase. Another group (Smad 4) includes Smads that are not direct receptor substrates, but participate in signaling by associating with receptor-activated Smads. The third group of Smads (Smad6 and Smad7) consists of proteins that inhibit activation of Smads in the first two groups.

Smads have specific roles in pathways of different TGF- β family members. Among Smad proteins identified for TGF- β family members, Smad2 and Smad3 are specific for TGF- β signaling (Heldin et al., *Nature* 390:465-471, 1997). The activated Smad2 and Smad3 interact with common mediator Smad4 and translocate into nuclei, where they activate a set of specific genes (Heldin et al., *Nature* 390:465-471, 1997). The TGF- β pathway uses the signal inhibitory proteins Smad6 and Smad7 to balance the net output of the signaling, as well as direct activation of Smad2 and/or Smad3. In the case of BMP-mediated signaling, following binding of a BMP to a BMP receptor, Smad1 and Smad5 are recruited to the receptor and phosphorylated. Once these proteins are phosphorylated, Smad1 and Smad5 form a complex with Smad4, and

the complex translocates to the nucleus, resulting in activation of BMP-mediated gene transcription.

While Smad2 and Smad3 have intrinsic transactivation activity as transcription factors (Zawel et al., *Mol Cell* 1:611-617, 1998), studies have demonstrated that they activate specific gene expression largely through specifically interacting with other nuclear factors (Derynck et al., *Cell* 95:737-740, 1998). A specific TGF- β -mediated effect on a given cell type can be achieved by activating a specific Smad protein, resulting in alterations in expression of specific genes. The interplay or crosstalk of different signal transduction pathways is essential to provide balanced and integrated response to total signals to a given cell under given conditions. TGF- β -induced signaling has been found to crosstalk at the Smad level with Ras-mediated MAP kinase pathway and Jak/Stat pathway (Ulloa et al., *Nature* 397:710-3, 1999; Kretzschmar et al., *Nature* 389:618-22, 1997).

As noted above, TGF- β plays a role in the regulation of cell growth. TGF- β can be a growth stimulator or growth inhibitor, depending on the type or/and growth stage of the responding cells. As a potent negative epithelial cell growth regulator, TGF- β plays an important role in epithelial carcinogenesis (Cui et al., *Cell* 86:531-542, 1996). TGF- β has been shown to cause cell growth arrest by inducing cyclin-dependent kinase inhibitors such as p15 and p21 (Hannon et al., *Genes Dev.* 9:1831-45, 1995), and a TGF- β type II receptor mutation that makes cells resistant to TGF- β leads to an enhancement of tumorigenic state of cells (Markowitz et al., *Science* 268:1336-8, 1995). Mutations in Smad genes have also been associated with cancer. Some colon cancers have found to carry mutations in tumor suppressor protein Smad2 (Eppert et al., *Cell* 88:543-552, 1996; Hata et al., *Nature* 388:82-87, 1997). It also has been shown that Smad4 is a tumor suppressor gene in human pancreatic carcinomas and perhaps in other tumors. Smad3 mutant mice develop metastatic colorectal cancer (Zhu et al., *Cell* 94:703-714, 1998), suggesting that Smad3 may play role in human colon cancer. In other contexts, TGF- β and TGF- β pathway members appear to play cell growth promoting roles. At early stages of carcinogenesis, TGF- β has been reported to act as a tumor promoter. At later stage, TGF- β can stimulate malignant progression. It

has recently been demonstrated that TGF- β is directly involved in promoting malignancy following organ transplantation (Hojo et al., *Nature* 397:530-534, 1999). Thus, TGF- β can promote tumor cell invasion and metastasis, and methods for modulating TGF- β signaling could provide opportunities to develop effective cancer therapy.

Although certain aspects of TGF- β - and BMP-mediated signaling are understood, further knowledge of these signaling pathways is needed to facilitate the development of therapeutic agents that modulate such signaling. Accordingly, there is a need in the art for an improved understanding of the molecular mechanisms of TGF- β - and BMP-mediated signaling and for the development of agents that modulate such signaling. The present invention fulfills these needs and further provides other related advantages.

SUMMARY OF THE INVENTION

Briefly stated, the present invention provides methods for identifying agents that modulate signal transduction mediated by TGF- β and/or other member(s) of the TGF- β family, such as BMP. Within certain aspects, such methods comprise the steps of (a) contacting (i) a first polypeptide comprising a HECT E3 ubiquitin ligase WW domain, or a variant thereof in which the ability of the polypeptide to bind to a Smad protein is not substantially diminished relative to the HECT E3 ubiquitin ligase; (ii) a second polypeptide comprising a Smad PY motif, or a variant thereof in which the ability of the polypeptide to bind to an E3 ubiquitin ligase is not substantially diminished relative to a native Smad protein comprising the PY motif; and (iii) a candidate agent; wherein the step of contacting is performed under conditions that permit a detectable level of binding of the first polypeptide to the second polypeptide in the absence of candidate agent; (b) determining a level of binding of the first polypeptide to the second polypeptide; and (c) comparing the level of binding to a control level of binding of the first polypeptide to the second polypeptide in the absence of candidate agent.

5

Within other aspects, such methods comprise the steps of: (a) contacting (i) a candidate agent; (ii) a ubiquitinated HECT E3 ubiquitin ligase; and (iii) a Smad protein or a variant thereof that comprises a PY motif; wherein the contact takes place under conditions and for a time sufficient to permit ubiquitination of the Smad protein or variant thereof by the HECT E3 ubiquitin ligase in the absence of candidate agent; (b) determining a level of ubiquitination of the Smad protein or variant thereof; and (c) comparing the level of ubiquitination to a control level of ubiquitination in the absence of candidate agent.

Within further aspects, such methods comprise the steps of: (a) contacting a cell that expresses a TGF- β or BMP receptor with BMP or TGF- β , and a candidate agent; and (b) detecting a level of a Smad protein in the bone cell, relative to a level of the Smad protein in a cell that is contacted with the bone morphogenic protein in the absence of the candidate agent.

Still further such methods comprise the steps of: (a) contacting a cell that expresses a TGF- β or BMP receptor with TGF- β or BMP and a candidate agent; and (b) detecting a level of ubiquitination of a Smad protein in the cell, relative to a level of the Smad protein ubiquitination in a cell that is contacted with the bone morphogenic protein but is not contacted with the candidate agent.

Within other such aspects, a method for screening for an agent that modulates TGF- β - or BMP-mediated signaling comprises the steps of: (a) contacting a cell that expresses a TGF- β or BMP receptor with TGF- β or BMP and a candidate agent; and (b) detecting a level of a HECT E3 ubiquitin ligase activity in the cell, relative to a level of HECT E3 ubiquitin ligase activity in a cell that is contacted with TGF- β or BMP in the absence of the candidate agent.

The present invention further provides, within other aspects, methods for augmenting TGF- β - or BMP-mediated signaling in a cell, comprising contacting a cell with an agent that inhibits binding of a HECT E3 ubiquitin ligase WW domain to a Smad PY motif and/or inhibits ubiquitination of a Smad protein.

Within further aspects, the present invention provides methods for stimulating bone formation in a patient, comprising administering to a patient a

therapeutically effective amount of an agent that inhibits binding of a HECT E3 ubiquitin ligase WW domain to a Smad PY motif and/or inhibits ubiquitination of a Smad protein.

The present invention further provides, within other aspects, methods for preventing or treating a condition associated with insufficient TGF- β - or BMP-mediated cell signaling, comprising administering to a patient a therapeutically effective amount of an agent that inhibits binding of a HECT E3 ubiquitin ligase WW domain to a Smad PY motif and/or inhibits ubiquitination of a Smad protein.

These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a diagram illustrating the general mechanism for ubiquitin (Ub) ligation to targeted proteins. Ubiquitination is initiated by ATP-dependent transfer of a ubiquitin monomer to enzyme 1 (E1) in the ubiquitin cascade. Following ubiquitin activation on E1, a transfer of ubiquitin to a ubiquitin carrier protein (E2) occurs. Transfer of the ubiquitin to a targeted protein is mediated by ubiquitin ligases (E3's).

Figure 2 is a Western blot illustrating the induction of Smad1 degradation by BMP. The level of tagged Smad1 in transfected cells following treatment with BMP and/or LLF (Leu-Leu-Phe, a proteasome inhibitor) is shown, as indicated.

Figure 3 is a Western blot illustrating Smad1 ubiquitination. COS cells expressing HA-tagged Smad1 were treated with one or more of BMP, LLF and/or ubiquitin (Ub), as indicated. Cells were lysed and Smad1 was immunoprecipitated. Western blots were probed with Anti-HA and anti-ubiquitin antibodies, as indicated.

Figure 4 is an autoradiogram illustrating the binding of WWP1.1 to the PY motif of Smad1. Untransfected COS cells (COS), or COS cells transfected with HA-tagged Smad1 or altered Smad1 with a mutated PY motif (Smad1*), were lysed.

Smad1 was immunoprecipitated and incubated with ^{32}P -labeled GST-fusion proteins of the WWP1.1 WW domain. Bound WWP1.1 was then detected autoradiographically, as indicated.

Figures 5A-5D are histograms illustrating the binding of PY motif peptides to WWP1 WW domain peptides. Four GST fusion peptides were assayed: GST-WWP1.1 (Figure 5A), GST-WWP1.2 (Figure 5B), GST-WWP1.3 (Figure 5C) and GST-WWP1.4 (Figure 5D). In each panel, binding to GST alone is also shown (cross-hatched columns, as indicated). WW domain peptides were coated on polystyrene plates at the indicated receptor coating concentrations, and blocked with BSA. Biotinylated PY motif peptides (Nedd, mutant Nedd and WBP1) were then added as indicated. Binding was assessed using a time-resolved fluorescence assay and is shown as binding activity (cps).

Figures 6A-6D are graphs illustrating the binding of Smad PY motif peptides to WWP1 WW domain peptides. Four GST fusion peptides were assayed, and are shown in each graph: GST-WWP1.1, GST-WWP1.2, GST-WWP1.3 and GST-WWP1.4. Binding to GST alone is also shown (open squares). WW domain peptides were coated on polystyrene plates at the indicated receptor coating concentrations, and blocked with BSA. Biotinylated PY motif peptides (Smad7 (Figure 6A); Smad6 (Figure 6B); Smad2 (Figure 6C) and Smad3 (Figure 6D)) were then added as indicated. Binding was assessed using a time-resolved fluorescence assay and is shown as cps.

Figures 7A-7B are graphs illustrating the binding of Smad PY motif peptides to WWP1 WW domain peptides. Four GST fusion peptides were assayed, and are shown in each graph: GST-WWP1.1, GST-WWP1.2, GST-WWP1.3 and GST-WWP1.4. WW domain peptides were coated on polystyrene plates at the indicated receptor coating concentrations, and blocked with BSA. Biotinylated PY motif peptides (Smad5 (Figure 7A) and Smad1 (Figure 7B)) were then added as indicated. Binding was assessed using a time-resolved fluorescence assay and is shown as cps.

Figures 8A-8B are graphs illustrating the binding of increasing concentrations of a Smad7 PY motif peptide to WWP1 WW domain peptides. In Figure 8A, binding to four GST fusion peptides (GST-WWP1.1, GST-WWP1.2, GST-

WWP1.3 and GST-WWP1.4) is shown, as well as binding to RSP5.2 WW domain. WW domain peptides were coated on polystyrene plates at the indicated receptor coating concentrations, and blocked with BSA. Biotinylated PY motif peptide was then added at the indicated concentrations. Binding was assessed using a time-resolved fluorescence assay and is shown as cps. Figure 8B presents a Scatchard analysis of the Smad7 PY motif to WWP1.2 and WWP1.4, as indicated.

Figures 9A-9C are autoradiograms illustrating the activation and activity of E1 in a coupled ubiquitination assay. Figure 9A shows ubiquitinated E1 (lane 2), where the presence of E1-covalently linked to labeled ubiquitin is shown by the indicated high molecular weight band. In figure 9B, bands indicating ubiquitinated E1 and E2 (UBC5c) are shown in lane 1, and this ubiquitination is not present in lane 2 (reaction performed in the absence of E1) or lane 3 (reaction performed in the presence of DTT). Figure 9C shows ubiquitinated E1 and E2 (UBC7) in lane 1, and this ubiquitination is not present in lane 2 (reaction performed in the absence of E1) or lane 3 (reaction performed in the presence of DTT).

Figures 10A-10C are autoradiograms illustrating the ubiquitination of the HECT E3 ligase WWP1 WW domain in a coupled ubiquitination assay. In each Figure, incorporation of labeled ubiquitin into a WWP1 HECT domain containing residues 611-985 or 611-990 is shown, as indicated. Reactions were performed in the presence or absence of DTT, as indicated. Ubiquitinated WWP1-GST is indicated by the arrow. In Figure 10A the E2 was UBC5c, and in Figure 10B the E2 was UBS7. Controls (Figure 10C) were performed in the absence of E2.

Figures 11A-11C are autoradiograms illustrating the ubiquitination of the HECT E3 ligase WWP1 in a coupled ubiquitination assay. In each Figure, incorporation of labeled ubiquitin into a WWP1 HECT domain containing residues 611-985 is shown. Also shown are ubiquitinated E1 and E2. Reactions were performed in the presence or absence of DTT, as indicated. In Figure 11A the E2 was UBC5c, and in Figure 11B the E2 was UBS7. Controls (Figure 11C) were performed in the absence of E2 (lane 1) or in the absence of E1 and E2 (lane 2).

Figures 12A-12C are autoradiograms illustrating the time course of ubiquitination of the HECT E3 ligase WWP1 in a coupled ubiquitination assay. In each Figure, incorporation of labeled ubiquitin into a WWP1 HECT domain containing residues 611-985 following various incubation times, as indicated, is shown. In Figure 12A the E2 was UBC5c, and in Figure 12B the E2 was UBS7. A control (Figure 12C) was performed in the absence of E2, in a 60 minute reaction.

DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed to methods for identifying agents that modulate signaling mediated by one or more TGF- β family members (*e.g.*, transforming growth factor beta (TGF- β) or bone morphogenic protein (BMP)), and to methods for using such agents for therapeutic purposes. The agents identified using the methods provided herein generally modulate such signaling by targeting specific Smad proteins inside cells. Such agents provide a powerful way to alter the response of cells to TGF- β family members.

The present invention is based, in part, on the discovery that signaling mediated by TGF- β family members is dampened by ubiquitin-mediated degradation of certain Smad proteins (such as Smad1 and Smad5 for BMP, or Smad2 and Smad3 for TGF- β). The ubiquitin-mediated degradation is generally induced by the TGF- β family member(s) involved in triggering signaling. Further, it has been found within the context of the present invention that HECT E3 ubiquitin ligases that contain a WW domain bind to a PY motif in certain Smad proteins, resulting in ubiquitination and proteasome-mediated degradation of the target Smads. Agents that inhibit binding between a HECT E3 WW domain and a Smad PY motif may generally be used to inhibit degradation of a Smad protein (*i.e.*, stabilize the Smad protein), resulting in enhanced TGF- β family member-mediated signaling.

Ubiquitin-mediated protein degradation is regulated by the ubiquitin conjugating pathway (Figure 1). Within this pathway, selective ubiquitination is initiated by ATP-dependent transfer of a ubiquitin monomer to enzyme 1 (E1) in the ubiquitin cascade. Ubiquitin bound to E1 is then activated with ATP to form an

ubiquitin-AMP intermediate. The AMP is displaced by the E1 active site cysteine to form a thioester linkage with the carboxy terminus of ubiquitin. A second activated ubiquitin is then formed by E1, which allows the E1 to transfer ubiquitin from its active site cysteine to the active site cysteine of a ubiquitin carrier protein (E2). During this transfer, diversity in the ubiquitination pathway begins to initiate and amplify. The greatest degree of selectivity in the ubiquitination cascade occurs at the level of ubiquitin transfer, ligation and polymerization on selected substrates. This terminal step is mediated by ubiquitin ligases (E3's). E2 either transfers the ubiquitin from its active site to the cysteine of an E3 ubiquitin ligase or to the target protein in an E3-dependent manner. Following transfer and ligation of ubiquitin onto substrates by E3, the ubiquitinated protein is targeted for degradation by the 26S proteasome. Selectivity for proteasome-mediated protein degradation is determined by the ubiquitin tag.

As used herein, a HECT E3 ubiquitin ligase is an E3 ubiquitin ligase that contains a HECT (Homologous to E6 Carboxyl Terminus) sequence within the catalytic carboxyterminal domain. Preferred HECT sequences satisfy the following consensus sequence:

(Y/F)X₍₂₋₃₎YX₍₈₋₁₁₎WFWXI(V/I/L)X₅EX(K/R)X₃(L/V)QF(V/L)TG(T/S)XRLP
 (L/V/M/A/I)XGFXXLX₍₄₋₁₀₎IX₍₇₋₉₎LPXXHTCFNXLDLPXYXSX₃(L/M)X₂
 (R/K)LX₂AIX₍₄₋₆₎F (SEQ ID NO:1)

wherein X = any amino acid; (Y/F) = Y preferred over F.

E3 ubiquitin ligases are members of the ubiquitination cascade that transfer ubiquitin to specific substrates, rendering the substrates targets for proteasome-mediated degradation. Known HECT E3 ubiquitin ligases include, for example, WWP1 (Pirozzi et al., *J. Biol. Chem.* 272:14611-16, 1997), E6-associated protein (E6-AP; Huibregtse et al., *Mol. Cell. Biol.* 13:775-84, 1993), Rsp5 (Huibregtse et al., *Proc. Natl. Acad. Sci. USA* 92:2563-67, 1995) and Nedd4 (Staub et al., *EMBO J.* 15:2371-80, 1996). Other HECT E3 ubiquitin ligases may be identified based on sequence similarity to known proteins and/or the presence of functional properties of HECT E3 ligases. A variety of techniques may be used to evaluate sequence similarity. One such technique is searches of sequence databases (e.g., GenBank). Such searches may be performed

using well known programs (e.g., NCBI BLAST searches), and proteins that display high levels of sequence identity and/or similarity are candidate HECT E3 ligases. Alternatively, techniques employing low stringency hybridization may facilitate the identification of a HECT E3 ligase. Within such techniques, a known HECT E3 ubiquitin ligase (or a portion thereof) is used as a probe to screen a library (cDNA or genomic) for hybridizing sequences. Suitable low stringency hybridization conditions include, but are not limited to, 1.0 x SSPE or SSC, 0.1% SDS, 50°C. Yet another technique for evaluating sequence similarity employs PCR reactions that are performed using degenerate primers that encode a conserved sequence.

Alternatively, or in addition, a functional assay may be used to identify a HECT E3 ubiquitin ligase. Certain assays detect binding to substrates, such as Smad proteins or portions thereof (e.g., portions comprising a PY motif as described herein). Such assays are well known in the art, and include affinity purification, yeast two-hybrid screens and screens of phage display libraries. Methods for performing these and other binding assays are amply described in the patent and scientific literature (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989; Brachman and Boeke, *Current Opinion in Biotechnology* 8:5661-568, 1997; and references cited therein). Other functional assays may be designed to assess ubiquitin transferring activity of a candidate HECT E3 ubiquitin ligase. Such assays may be performed using known techniques (e.g., coupled ubiquitin assays or ubiquitin dependent proteolysis assays in which the activity of E3 for transferring ubiquitin to a substrate is coupled with a measurement of substrate proteolysis), which are described in greater detail below. A HECT E3 ubiquitin ligase should display detectable ubiquitin transferring activity within such assays.

A Smad protein is a protein that is homologous to a known Smad protein (i.e., displays at least 50% primary sequence identity in the MH2 domain), and that participates in signal transduction mediated by a TGF- β family member (i.e., expression of a Smad protein detectably enhances or inhibits such signal transduction as measured using any assay suitable for the particular TGF- β family member). Smad proteins of particular interest include Smad1 (Hoodless et al., *Cell* 89:1165-1173, 1996), Smad2

(Nakao et al., *J. Biol. Chem* 272:2896-2900, 1997), Smad3 (Zhang et al., *Nature* 383:168-172, 1996), Smad5 (Liu et al., *Nature* 381:620-623, 1996), Smad6 (Imamura et al., *Nature* 389:622-626, 1997) and Smad7 (Hayashi et al., *Cell* 89:1165-1173, 1997). It will be apparent, however, that any Smad protein that contains a PY motif as described herein may be stabilized using the methods provided herein.

ASSAYS FOR AGENTS THAT MODULATE TGF- β FAMILY MEMBER-MEDIATED SIGNALING

Screening assays for agents that modulate TGF- β - and/or BMP-mediated signaling, or signaling mediated by one or more other TGF- β family members, may be performed in a variety of formats, including cell-based and *in vitro* assays. In general, such an assay should evaluate the effect of an agent on: (1) binding of a HECT E3 ubiquitin ligase WW domain to Smad PY motif; (2) ubiquitination of a Smad protein by E3 ubiquitin ligase; (3) proteolysis of a Smad protein (*e.g.*, by assessing the cellular level of a Smad protein) or (4) HECT E3 ubiquitin ligase activity. For assays involving Smad proteins, agents that modulate BMP-mediated signaling may be identified through the use of Smad1 or Smad5 (or a variant of Smad1 or Smad5). Similarly, agents that modulate TGF- β -mediated signaling may be identified through the use of Smad2 or Smad3 (or a variant of Smad2 or Smad3).

Candidate agents that may be screened within the assays provided herein include, but are not limited to, antibodies and antigen-binding fragments thereof, competing peptides that correspond to a WW domain or PY motif, and other natural or synthetic molecules, such as small molecule inhibitors, that bind to a HECT E3 ubiquitin ligase or Smad protein. Candidate agents may be present within a library (*i.e.*, a collection of compounds). Such agents may, for example, be encoded by DNA molecules within an expression library. Other such agents include compounds known in the art as "small molecules," which have molecular weights less than 10^5 daltons, preferably less than 10^4 daltons and still more preferably less than 10^3 daltons. Such candidate agents may be provided as members of a combinatorial library, which includes synthetic agents (*e.g.*, peptides) prepared according to multiple predetermined chemical reactions. Those having ordinary skill in the art will appreciate that a diverse

assortment of such libraries may be prepared according to established procedures, and members of a library of candidate agents can be simultaneously or sequentially screened as described herein.

In vitro assays may be used for rapid screening of candidate agents for the ability to inhibit binding of a HECT E3 ubiquitin ligase to a Smad protein. As noted above, this binding has been found, within the context of the present invention, to take place between the WW domain of HECT E3 ubiquitin ligase and the PY motif of certain Smad proteins. Accordingly, any *in vitro* assay that assesses the effect of a candidate agent on this interaction may be used to identify agents that modulate TGF- β family member-mediated signaling (*i.e.*, signaling mediated by one or more members of the TGF- β family, including TGF- β , BMP, activin(s) and/or inhibin(s)). Such assays typically assess the effect of an agent on binding between a polypeptide comprising a HECT E3 WW domain, or a variant thereof, and a polypeptide comprising a Smad PY motif, or a variant thereof.

A HECT E3 WW domain, as used herein, is a region of a HECT E3 ubiquitin ligase that contains two tryptophan residues 20 to 22 amino acid residues apart (*see* M. Sudol, *Prog. Biophys. Molec. Biol.* 65:113-132, 1996), and detectably binds to a Smad PY motif, as described herein. Within preferred embodiments, a WW domain satisfies the following consensus sequence:

GPLPXGWEX₃tttGtXYYhXHNTtTTtWXtPt (SEQ ID NO:2)

wherein each t is an independently selected polar amino acid residue (*e.g.*, S, H, P, D, E, T or Y), h is a hydrophobic residue (*e.g.*, I, V, L or M) and X is any amino acid. Within this and other sequences provided herein, amino acid residues are indicated using the standard one- or three-letter code.

Representative HECT E3 ubiquitin ligase WW domains include: SPLPPGWEERQDILGRYYVNHEsrRTQWKRPTPDNL (human Nedd4; SEQ ID NO:3), SGLPPGWEERQDILGRYYVNHEsrRTQWKRPTPDNL (human Nedd4; SEQ ID NO:4), GFLPKGWEVRHAPNGRPFFIDHNTKTTTWEDPRLKIPA (human Nedd4; SEQ ID NO:5), GPLPPGWEERTHTDGRIFYINHNIKRTQWEDPRLNVA

14

(human Nedd4; SEQ ID NO:6), GRLPPGWERRTDNFGRTYYVDHNTRTTT WKRP TL DQTE (yeast Rsp5; SEQ ID NO:7); GELPSGWEQRFTPEGRAYFVD HNTRTTTWVDP RRQYI (yeast Rsp5; SEQ ID NO:8); GPLPSGWEMRL TNTARVYFVDHN TKTTTWDDPRLPSSL (yeast Rsp5; SEQ ID NO:9); LPSGWGWEQRKDPHGRTYYVDHNTRTTTWERPQPLPPG (SEQ ID NO:10; WWPI WW domain 1); QPLPPGWERRVDDR RVYYVDHNTRTTTW QRPTMESVR (SEQ ID NO:11; WWPI WW domain 2); GPLPPGWEKRVDSTDRVYFVNHN TKTTQWEDPRTQGLQ (SEQ ID NO:12; WWPI WW domain 3) and EPLPEGWEIRYTREGVRYFVDHNTRTTTTFK DPRNGKSS (SEQ ID NO:13; WWPI WW domain 4). Within the assays provided herein, a polypeptide comprising a WW domain may be a full length HECT E3 ubiquitin ligase, a portion thereof that comprises a WW domain, or a variant of such a polypeptide in which the WW domain is modified by one or more substitutions, additions, insertions and/or deletions such that the ability of the variant to bind to a Smad PY motif is not substantially diminished (*i.e.*, is enhanced, unchanged or diminished by no more than 10%), relative to the native WW domain sequence. This binding activity may be assessed using a representative binding assay provided herein.

A Smad PY motif is a 10-14 consecutive amino acid portion of a Smad protein that contains a PPxY (Pro-Pro-Xaa-Tyr; SEQ ID NO:14) sequence, in which x and Xaa both represent any amino acid. Such a PY motif further binds detectably to a HECT E3 ubiquitin ligase WW domain, as provided herein. Representative Smad PY motifs are present, for example, within Smads 1, 2, 3, 5, 6 and 7. Smad PY motifs preferably satisfy the consensus sequence Ser/Thr-Pro-Pro-Pro-Pro/Ala/Gly-Tyr (SEQ ID NO:15), wherein Ser/Thr is an amino acid residue that is serine or threonine and Pro/Ala/Gly is an amino acid residue that is selected from the group consisting of proline, alanine and glycine. For Smads 1 and 5 (which are involved in BMP-mediated signal transduction) a PY motif comprises the sequence TPPPAY (SEQ ID NO:16), preferably PADTPPPAY(L/M)PPPD (SEQ ID NO:17). For Smads 2 and 3 (which are involved in TGF- β -mediated signal transduction) a PY motif comprises the sequence TPPPGY (SEQ ID NO:18), preferably TPPPGY(I/L)SEDG (SEQ ID NO:19).

Polypeptides comprising a Smad PY motif may comprise, for example, a sequence such as ELESPPPPYSRYPM (SEQ ID NO:20), GPESPPPPYSRLSP (SEQ ID NO:21), PADTPPPAYLPPED (SEQ ID NO:22), PADTPPPAYMPPDD (SEQ ID NO:23), IPETPPPGYISEDG (SEQ ID NO:24) or AGLTPPPGYLSEDG (SEQ ID NO:25). Within the assays provided herein, a polypeptide comprising a PY motif may be a full length Smad protein, a portion thereof that comprises a PY motif, or a variant of such a polypeptide in which the PY motif is modified by one or more substitutions, additions, insertions and/or deletions such that the ability of the variant to bind to a HECT E3 ubiquitin ligase WW domain is not substantially diminished (*i.e.*, is enhanced, unchanged or diminished by no more than 10%), relative to the native PY motif sequence. This binding activity may be assessed using a representative binding assay provided herein.

Preferably, a WW domain or PY motif polypeptide variant contains conservative substitutions. A "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydrophathic nature of the polypeptide to be substantially unchanged. Amino acid substitutions may generally be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also, or alternatively, contain nonconservative changes. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the secondary structure and hydrophathic nature of the polypeptide.

WW domain and PY motif polypeptides may comprise additional sequences that are unrelated to an endogenous protein. Such sequences include signal (or leader) sequences at the N-terminal end of the protein that co-translationally or post-translationally direct transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (*e.g.*, poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

The WW domain polypeptide and PY motif polypeptide are contacted under conditions that permit binding between the two polypeptides in the absence of a candidate agent. Candidate agent may be added to the reaction mixture before or after contact of the WW domain polypeptide with the PY motif polypeptide. The reaction is then incubated, and binding of the WW domain polypeptide to the PY motif polypeptide is assessed, using any standard technique. One suitable binding assay employs a solid support, as described above, to which one of the polypeptides is attached. Binding may be assessed by removing unbound substances and detecting the presence of the other polypeptide on the solid support. Such detection may be achieved using, for example, an antibody or antigen-binding fragment detection reagent, or using a competitive assay with labeled polypeptide, as described above. Alternatively, the polypeptide that is not immobilized on the support may itself comprise a tag that facilitates detection of bound polypeptide. Tags include, but are not limited to, biotin, enzymes, radioactive groups (*e.g.*, ^{32}P), dyes, luminescent groups, fluorescent groups and other sequences that are readily bound by a detection reagent (*e.g.*, antigenic sequences specifically bound by particular antibodies). In general, an agent should detectably modulate binding between the WW domain polypeptide and PY motif polypeptide.

By way of example, one polypeptide (*i.e.*, a WW domain polypeptide or PY motif polypeptide) may be immobilized through non-specific interactions (*e.g.*, to a polystyrene plate) or through a protein tag interaction (*e.g.*, an interaction between a His₆-fusion protein and a nickel plate). The polypeptide may be immobilized by, for example, contacting a polystyrene assay plate (Costar) with the polypeptide overnight at

4°C in a 200 mM carbonate buffer (Pierce, Rockford IL) at a concentration ranging from 0.3 to 30 µg/mL. Unbound polypeptide may be removed by washing with distilled, deionized water and the plates may then be blocked with 1% BSA/carbonate buffer for two hours at room temperature. Plates may then be washed with Tris/Tween buffer (50 mM Tris pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% BSA, 1 mM DTT 0.1% Tween20, protease inhibitor cocktail (Boehringer-Mannheim). The other polypeptide may be labeled (e.g., biotinylated) and allowed to bind to the immobilized polypeptide (e.g., solvated in Tris/Tween buffer and incubated in the assay plates at 4°C for varying amounts of time). Plates may then be washed with PBS/0.1% Triton X100. Binding may be detected by, for example, probing the assay wells with 1 µg/mL Europium-labeled streptavidin (DELFI A; Wallac Oy, Turku, Finland) in DELFI A Assay Buffer/0.1% Triton X100 for one hour at room temperature. Unbound Europium-labeled streptavidin may be removed by washing with PBS/0.1% Triton X100. Europium may be released for time-resolved fluorescence (TRF) measurements with the DELFI A Enhancement Buffer. TRF measurements may be made, for example, with a DELFI A 1234 (Wallac Oy, Turku, Finland) fluorometer.

Within similar assays, a radioactive label may be substituted for the biotin. For example, a ³²P-labeled polypeptide may be generated by phosphorylation of a suitable site linked to the WW domain polypeptide or PY motif polypeptide. One such site is the PKA site in the pGEX KG vector (Pharmlngen), which may be labeled using α-[³²P]-ATP and protein kinase A (Sigma). The amount of binding may be quantitated by, for example, Cerenkov counting or SDS-PAGE using standard techniques. The solid support used may also be varied. One suitable support for such assays is neutravidin agarose beads (Pierce, Rockford, IL). Binding may be performed using such a support by incubation in a PBS/1% Tween20 buffer in an end-over shaker at 4°C for varying amounts of time. It will be apparent that any of these assays may be modified to permit immobilization after binding takes place.

To determine the effect of a candidate agent on binding of the WW domain to the PY motif, the level of binding is compared in the presence and absence of candidate agent. An agent that detectably inhibits or enhances such binding may be

used to alter TGF- β family member-mediated signaling in a cell. Preferred agents modulate TGF- β and/or BMP-mediated signaling.

Other *in vitro* assays may be designed to assess the effect of an agent on ubiquitination of an E3 ubiquitin ligase and/or a Smad. *In vitro* ubiquitination reactions are well known in the art. For example, coupled ubiquitination assays (in which ubiquitin transfer from E1 to E2, and from E2 to E3, is monitored) may be employed. Such assays require the reconstitution of an E1/E2/E3 pathway. Recombinant E1 and E2 components are available from a variety of sources (*e.g.*, BostonBiochem, Cambridge, MA) for coupling ubiquitin to an E3 ligase of interest. Radiolabeled ubiquitin may be generated using standard techniques, such as PKA-mediated incorporation of [32 P]-phosphate from α -[32 P]-ATP to the PKA site of the GST-ubiquitin fusion protein (pGEX KG expression vector). One suitable ubiquitin assay buffer is: 50 mM Tris pH7.6, 1 mM ATP, 0.2 mM EDTA, 5 mM MgCl₂, 1 unit inorganic pyrophosphatase, 0.005% Triton X100 and 1 μ M staurosporine. In a 0.030 mL reaction, the following amounts of reaction components are generally suitable: 50-200 ng E1, 0.1-1 μ g E2, 5 μ g GST-ubiquitin (BostonBiochem, Cambridge, MA) and 50-200 ng E3. Reactions may be performed at room temperature and terminated with a SDS-PAGE loading buffer that does not contain mercaptans. Reactions may be analyzed by SDS-PAGE. An assay may be similarly performed with endogenous proteins from, for example, HeLa cell extract fractions (*see* Hershko et al., *J. Biol. Chem.* 258:8206-8214, 1983). For measuring Smad protein ubiquitination, a Smad polypeptide is included in the reaction. These assays may be further modified to measure Smad protein degradation by incorporation of 100-1000 ng of 20S proteasome (Boston Biochem, Cambridge, MA) into the assay.

A Smad polypeptide for use within such an assay may be tagged to facilitate detection of covalently attached ubiquitin. Such a polypeptide may be a full length Smad protein, or may be a truncated protein or a variant thereof, provided that the polypeptide contains a functional PY motif and ubiquitination site. A ubiquitination site may be identified based on criteria known in the art. For example, ubiquitination generally occurs on lysine residues within 100 amino acids of the HECT/WW binding

site. Similarly, a HECT E3 ubiquitin ligase for use within such assays may be a full length protein, a truncated protein or a variant thereof, provided that the ligase contains a functional WW domain and HECT domain and ubiquitinates a Smad protein of interest.

Cell-based assays (*i.e.*, assays in which intact cells are exposed to a candidate agent) may be used to detect the effect of an agent on Smad protein degradation in a cellular environment. Such assays may be performed using any cell that expresses a receptor for a TGF- β family member ligand. Within preferred embodiments, a cell expresses a TGF- β and/or bone morphogenic protein (BMP) receptor. Known BMP receptors include ALK2, 3 and 6 (*see* Attisano et al., *Cell* 68:97-108, 1992; ten Dijke et al., *Oncogene* 8:2879-2887, 1993). Known TGF- β and activin receptors have been described, for example, by Attisano et al., *Cell* 75:671-680, 1993; Attisano et al., *Mol. Cell. Biol.* 16:1066-1073, 1996; Ebner et al., *Science* 262:900-902, 1993; Lin et al., *Cell* 68:775-785, 1992; Mathews and Vale, *Cell* 65:973-982, 1991; and Tsuchida et al., *Proc. Natl. Acad. Sci. USA* 90: 11242-11246, 1993. Suitable cells may be readily identified using immunochemical methods (employing antibodies raised against known BMP or TGF- β receptors), by direct measurement of BMP or TGF- β binding to the cells or by the detection of a BMP- or TGF- β -mediated response in the cells following exposure to BMP or TGF- β . Such methods are well known in the art. Preferred methods for identifying suitable cells involve the use of a reporter gene in which expression is under the control of a TGF- β or BMP response element. In general, a cell should express a level of receptor that is detectable using any such assay. Cells that express a BMP receptor include, but are not limited to, bone cells, neurons and kidney cells. TGF- β receptors are generally widely expressed.

A cell that expresses a TGF- β family member receptor is contacted with an amount of the TGF- β family member that is sufficient to result in a detectable level of TGF- β family member-mediated signaling in the cell, using any assay for gene expression mediated by the TGF- β family member that is appropriate for the particular cell type. Such assays may be based on the detection of enhanced expression of TGF- β family member-regulated genes, such as via a hybridization or amplification-based

assay, or an assay for expression of a reporter gene operably linked to a TGF- β - or BMP-regulated promoter. Alternatively, such an assay may be a functional assay. For example, BMP treatment for 1-2 weeks stimulates differentiation of osteoblasts. Contact of such cells with BMP should be sufficient to result in differentiation, as detected by mineralization. In general, contact of a cell with 100 ng BMP for 2-24 hours is sufficient to result in a detectable level of BMP-mediated signaling in the cell.

To determine the effect of a candidate agent on TGF- β family member-mediated signaling, a cell is contacted with a TGF- β family member ligand as described above, and with a candidate agent. A cell may be contacted with both substances simultaneously or sequentially, in either order. The amount of agent employed will vary, depending on the type of agent and the specific assay used, but in general 1 to 50 μ M of a candidate agent is sufficient. Within preferred embodiments, the TGF- β family member is TGF- β or BMP.

Following contact with TGF- β family member and the candidate agent, TGF- β family member-induced Smad protein degradation (preferably Smad1, 2, 3, 5, 6 or 7 degradation) is assessed. It will be apparent that any of a variety of assays may be used to assess Smad protein degradation including, but not limited to, assays that detect the level of: (1) a Smad protein; (2) ubiquitination of a Smad protein; or (3) HECT E3 ubiquitin ligase activity in the cell. In each type of assay (described in greater detail below), the level detected is compared with a level detected in the same type of cell, under the same conditions, but in the absence of candidate agent. A statistically significant difference in the signal detected in the presence of candidate agent, relative to the signal detected in the absence of candidate agent, indicates that the agent modulates TGF- β family member-mediated signaling in the cell.

To assess the level of a Smad protein, well known immunochemical methods may be employed. Such methods typically use an agent, such as an antibody or antigen-binding fragment thereof, that specifically binds to the Smad protein. To perform such assays, cells are generally lysed and the lysate (with or without pretreatment) is contacted with antibody under conditions that permit antigen-specific binding. Bound antibody is then detected by means of a suitable detection reagent.

There are a variety of assay formats that may be used to detect the level of a Smad protein in a cell lysate. See, e.g., Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In one embodiment, an assay involves the use of binding agent immobilized on a solid support to bind to and remove the Smad protein from the remainder of the lysate. The bound Smad protein may then be detected using a detection reagent that contains a reporter group and specifically binds to the binding agent/Smad complex. Such detection reagents may comprise, for example, an antibody that specifically binds to the Smad protein. Alternatively, a competitive assay may be used, in which a Smad protein or portion thereof is labeled with a reporter group and allowed to bind to the immobilized binding agent after incubation of the binding agent with the lysate. The extent to which components of the lysate inhibit the binding of the labeled Smad polypeptide to the binding agent is indicative of the level of the Smad protein in the lysate.

A solid support for use in such assays may be any material known to those of ordinary skill in the art to which a binding agent may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the binding agent and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for a suitable amount of time (typically between about 1 hour and about 1 day). In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 μ g, and preferably about 100 ng to about 1 μ g, is sufficient to immobilize an adequate amount of binding agent.

In certain embodiments, the assay is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized on a solid support, commonly the well of a microtiter plate, with the lysate, such that a Smad protein within the sample is allowed to bind to the immobilized antibody (e.g., incubation for 30 minutes at room temperature). Unbound sample is then removed from the immobilized Smad-antibody complexes and a detection reagent (preferably a second antibody capable of binding to a different site on the Smad protein) containing a reporter group is added. The amount of detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

The level of ubiquitination of a Smad protein may be readily determined based on the alteration in electrophoretic mobility of the ubiquitinated protein. Briefly, cells may be lysed and proteins present within the lysate may be separated by SDS-PAGE. A protein of interest may be detected by Western blot analysis. Ubiquitination results in a shift in the apparent molecular weight of the protein to the higher molecular weight region of the gel. Quantitative or semi-quantitative results may be obtained using labeled secondary antibodies, or other detection reagents known in the art.

HECT E3 ubiquitin ligase activity in the cell may be evaluated by any of a variety of ubiquitination assays commonly used in the art. Such assays typically employ a tagged target protein and/or labeled ubiquitin. Ligase activity is then assessed using, for example, a coupled ubiquitination assay as described herein. Such assays generally employ E3 ubiquitin ligase (generally within a lysate, or partially or substantially purified from a cell lysate) to ubiquitinate the tagged target protein. Using radiolabeled ubiquitin, for example, the amount of ubiquitination of target protein may

be determined by scintillation counting following removal of unbound ubiquitin. Alternatively, the degradation of target protein may be directly assessed by SDS-PAGE resolution of the reactions and detection of the tag. Assays to detect ubiquitination and degradation of proteins are well known in the art, and representative assays are described herein.

In general, the effect of an agent on TGF- β family member-mediated signaling may be determined based on its activity within the above assays. For Smads that enhance BMP-mediated signaling (including Smads 1 and 5), agents that inhibit Smad protein degradation may be used to augment BMP-mediated signaling. Similarly, agents that enhance degradation of such Smad proteins may be used to inhibit BMP-mediated signaling. For TGF- β -mediated signaling, agents that inhibit Smad2 and/or Smad3 protein degradation may be used to augment signaling, and agents that enhance degradation of such Smad proteins may be used to inhibit signaling. Agents identified using the screens provided herein may be used within a variety of therapeutic contexts, as described in further detail below.

METHODS OF USE FOR AGENTS THAT MODULATE TGF- β FAMILY MEMBER-MEDIATED SIGNALING

Agents that modulate BMP-mediated signaling may be used for the prevention or treatment of conditions associated with insufficient or excess BMP-mediated signaling in certain cell types. In general, an agent that augments BMP-mediated signaling (*e.g.*, inhibits binding of a HECT E3 ubiquitin ligase WW domain to a Smad1 or Smad5 PY motif) is useful for stimulating bone anabolism, as well as treating broken bones, osteoporosis and acute or chronic renal failure. Agents that inhibit BMP-mediated signaling may be used, for example, within therapies for cancer, inflammation, aging and infectious diseases.

Similarly, agents that modulate TGF- β -mediated signaling may be used for the prevention or treatment of conditions associated with insufficient or excess TGF- β -mediated signaling in certain cell types. In general, an agent that inhibits TGF- β -mediated signaling (*e.g.*, enhances binding of a HECT E3 ubiquitin ligase WW domain

to a Smad2 or Smad3 PY motif) is useful for treating cancer, inflammation, neurodegeneration and fibrosis.

For administration to a patient, one or more agents are generally formulated as a pharmaceutical composition, which may be a sterile aqueous or non-aqueous solution, suspension or emulsion, and which additionally comprises a physiologically acceptable carrier (*i.e.*, a non-toxic material that does not interfere with the activity of the active ingredient). Any suitable carrier known to those of ordinary skill in the art may be employed in a pharmaceutical composition. Representative carriers include physiological saline solutions, gelatin, water, alcohols, natural or synthetic oils, saccharide solutions, glycols, injectable organic esters such as ethyl oleate or a combination of such materials. Such compositions may also comprise buffers (*e.g.*, neutral buffered saline or phosphate buffered saline), carbohydrates (*e.g.*, glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, antimicrobial compounds, chelating agents such as EDTA or glutathione, adjuvants (*e.g.*, aluminum hydroxide), inert gases and/or preservatives. Compositions of the present invention may also be formulated as a lyophilizate. Pharmaceutical compositions may also contain other compounds, which may be biologically active or inactive.

The compositions described herein may be administered as part of a sustained release formulation (*i.e.*, a formulation such as a capsule that effects a slow release of compound following administration). Such formulations may generally be prepared using well known technology and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site. Sustained-release formulations may contain a polypeptide, polynucleotide or modulating agent dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane. Carriers for use within such formulations are biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of release. The amount of active compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

Another delivery system for such agents is a colloidal dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system for use as a delivery vehicle *in vitro* and *in vivo* is a liposome (*i.e.*, an artificial membrane vesicle). It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2-4.0 μm can encapsulate a substantial percentage of an aqueous buffer containing large macromolecules. The targeting of liposomes can be classified based on anatomical and mechanistic factors. Anatomical classification is based on the level of selectivity, for example, organ-specific, cell-specific, and organelle-specific. Mechanistic targeting can be distinguished based upon whether it is passive or active. Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticuloendothelial system (RES) in organs which contain sinusoidal capillaries. Active targeting, on the other hand, involves alteration of the liposome by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.

To achieve cell or tissue specificity, agents may (in some instances) be administered topically. Other agents may be specific for a particular HECT E3/Smad protein interaction, and thus may have a specific target cell type or tissue. It may, however, be beneficial in certain instances to employ a targeting moiety to facilitate delivery of an agent to a desired site. A targeting moiety is any compound (*e.g.*, a monoclonal or polyclonal antibody, a protein or a liposome) or cell that facilitates the delivery of the agent to a target cell or tissue, thereby increasing the local concentration of the agent. Targeting moieties include antibodies or fragments thereof, receptors, ligands and other molecules that bind to cells of, or in the vicinity of, the target tissue. An antibody targeting agent may be an intact (whole) molecule, a fragment thereof, or a functional equivalent thereof. Examples of antibody fragments are F(ab')₂, -Fab', Fab and F[v] fragments, which may be produced by conventional methods or by genetic or protein engineering. Linkage is generally covalent and may be achieved by, for

example, direct condensation or other reactions, or by way of bi- or multi-functional linkers. Targeting moieties may be selected based on the cell(s) or tissue(s) at which the agent is expected to exert a therapeutic benefit.

As noted above, patients that may benefit from treatment with an agent that modulates TGF- β and/or BMP-mediated signaling are those that are afflicted with (or at risk for developing) a condition associated with insufficient or excess TGF- β and/or BMP-mediated signaling in certain cell types. Such conditions may be diagnosed using criteria accepted in the art for the condition, or by *in vitro* analysis of Smad protein level.

Agents may be administered to a patient by any procedure that is appropriate for the condition to be treated including, for example, topical, oral, nasal, intrathecal, rectal, vaginal, sublingual or parenteral administration, such as subcutaneous, intravenous, intramuscular, intrasternal, intracavernous, intrameatal or intraurethral injection or infusion. An appropriate dosage and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient and the method of administration. In general, an appropriate dosage and treatment regimen provides the agent(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival). For prophylactic use, a dose should be sufficient to prevent, delay the onset of or diminish the severity of a condition associated with TGF- β and/or BMP-mediated signaling. Optimal dosages may generally be determined using experimental models and/or clinical trials. The use of the minimum dosage that is sufficient to provide effective therapy is usually preferred. Patients may generally be monitored for therapeutic or prophylactic effectiveness using assays suitable for the condition being treated or prevented, which will be familiar to those of ordinary skill in the art. Suitable dose sizes will vary with the size of the patient, but will typically range from about 10 mL to about 500 mL for 10-60 kg animal.

27

The following Examples are offered by way of illustration and not by way of limitation.

28 EXAMPLES

Example 1

Ubiquitination of Smad Proteins and Initial Characterization of E3/Smad Protein Binding

This Example illustrates the BMP-induced ubiquitination of Smad proteins, and the identification of a HECT E3 ligase domain that binds to Smad proteins.

HA-tagged Smad1 expression vector was transfected into COS cells. The transfected cells were then treated with 100 ng BMP for 4 hours in the absence or presence of 50-100 μ M of the proteasome inhibitor Leu-Leu-Phe (LLF). The cells were lysed and equal amount of protein was loaded in each lane. Western analysis was performed using anti-HA antibody (BAbCo, Berkeley, CA). As shown in Figure 2, BMP induces Smad1 degradation and LLF blocks BMP-induced Smad1 degradation.

To assess the *in vivo* ubiquitination of Smad1, a Smad1 expression vector was transfected into COS cells. The transfected cells were treated with BMP and the proteasome inhibitor LLF, as described above. The cells were then lysed and equal amounts of protein were used for immunoprecipitation using anti-HA antibody to precipitate tagged-Smad1 protein. The immunoprecipitated Smad1 was run on SDS-PAGE, followed by a Western blot using anti-HA antibody or anti-ubiquitin antibody (BAbCo). Cells treated with LLF and cells treated with LLF plus BMP clearly accumulated more high molecular weight, ubiquinated-Smad1 protein (Figure 3).

To analyze the *in vitro* binding of Smads with various WW domains, HA-tagged Smad1 was expressed in COS cells. The expressed Smad1 was immunoprecipitated from the cell lysate. After extensive washing, the immunoprecipitated Smad1 was mixed with 32 P-labeled GST-fusion proteins of WWP1 WW domains. The binding products were washed and run on SDS-PAGE. COS extract and 32 P-labeled GST protein was used as controls. WWP1.1 (a GST fusion with the 1st WW repeat: LPSGWEQRKDPHGRTYYVDHNTRTTTWER

29

PQPLPPGWE (SEQ ID NO:26) was found to bind to Smad1 (Figure 4, lane 2), but not the Smad1 mutated at the PY motif (Figure 4, lane 3). The Smad 1 PY peptide sequence used was: Biotin-Ahx-PADTPPPAYLPPED-CONH₂ (SEQ ID NO:22), and the mutated Smad 1 PY peptide sequence was: Biotin-Ahx-PADTPPPAHLPPED-CONH₂ (SEQ ID NO:27).

These results indicate that BMP induces ubiquitination of Smad proteins, using a pathway that includes a HECT E3 ubiquitin ligase.

Example 2

Interaction Between HECT E3 Ubiquitin Ligase WW Domain and Smad Proteins PY Motif Peptides

This Example illustrates the binding of HECT E3 WW domains to PY motifs.

The HECT domain E3 ligase WWP1 has 4 WW domains (WWP1.1, 1.2, 1.3, 1.4) which interact with the WBP-1 PY motif peptide (Chen and Sudol, *Proc. Natl. Acad. Sci. USA* 92:7819-7823, 1995). The sequence for each domain is:

WWP1.1: LPSGWGWEQRKDPHGRTYYVDHNTRTTTWERPQPLPPG
(SEQ ID NO:10);

WWP1.2: QPLPPGWERRVDDRRRVYYVDHNTRTTTWQRPTMESVR
(SEQ ID NO:11);

WWP1.3: GPLPPGWEKRVDSTDRVYFVNHNTKTTQWEDPRTQGLQ
(SEQ ID NO:12;) and

WWP1.4: EPLPEGWEIRYTREGVRYFVDHNTRTTTFKDPRNGKSS (SEQ ID NO:13)

Each domain was individually expressed as a GST fusion protein. A TRF binding assay was used to evaluate interactions of PY motif peptides with these domains or GST alone. WW domains were bound to a 96-well polystyrene assay plate (Costar) overnight at 4°C in a 200 mM carbonate buffer (Pierce, Rockford, IL) at

different concentrations (0, 1, 3, 10 $\mu\text{g/mL}$). Unbound WW domain was washed away with distilled, deionized water and the plates were blocked with 1% BSA/carbonate buffer for 2 hours at room temperature. The plates were then washed with Tris/Tween buffer: 50 mM Tris pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% BSA, 1 mM DTT, 0.1% Tween20, protease inhibitor cocktail (Boehringer-Mannheim).

PY motif peptides were synthesized with a C_6 -linker and biotin tag. The following PY motifs were used:

WBP1: Biotin-Ahx-HPGT PPPPYTVGPG-CONH₂ (SEQ ID NO:28);

Nedd: Biotin-Ahx-IPGT PPPNYDSLRL-CONH₂ (SEQ ID NO:29);

Mutant Nedd: Biotin-Ahx-IPGT PPPNHDSLRL-CONH₂ (SEQ ID NO:30).

These biotinylated peptides were solvated in Tris/Tween buffer and added to the assay plates (30 μM). The plates were incubated at 4°C for varying amounts of capture time. The plates were then washed with PBS/0.1% Triton X100 and probed for 1 hour at room temperature with 1 $\mu\text{g/mL}$ Europium-labeled streptavidin (DELFI A; Wallac Oy, Turku, Finland) in DELFI A Assay Buffer/0.1% Triton X100. The unbound Europium-labeled streptavidin was washed with PBS/0.1% Triton X100. Europium was released for time-resolved fluorescence measurements with the DELFI A Enhancement Buffer. Measurements were made on either the DELFI A 1234 or Victor fluorometers.

The WBP1 peptide bound specifically to the WWP1 WW domains but not to GST (Figures 5A-5D). The other biotinylated peptides did not specifically interact with the WW domains or GST (Figures 5A-5D).

Smad PY motif peptides from Smad 1, 2, 3, 5, 6 and 7 (Table I) were then evaluated with the WW domains from WWP1 (Figures 6A-6D and 7A-7B). The GST-WW domain fusion proteins and GST alone were coated at 30 $\mu\text{g/mL}$ overnight. After blocking the wells with BSA, the WW domain peptides were titrated with the Smad PY motif peptides. Smad 7 peptide demonstrated a very potent interaction with the second WW domain of WWP1 (WWP1.2; Figures 6A-6D); much more potent than the reported WBP1 PY peptide (Figures 5A-5D). The Smad 5 and Smad 6 peptides had measurable interactions with the WWP1 WW domains but were modest compared to

31

the Smad 7 interactions (Figures 6A-6D and 7A-7B). There was no measurable interaction of PY motif peptides from Smad 1, 2 or 3.

Table I
Smad Protein PY Motifs

Smad Protein	PY Motif Peptide
Smad7	ELESPPPPYSRYPM (SEQ ID NO:20)
Smad6	GPESPPPPYSRLSP (SEQ ID NO:21)
Smad1	PADTPPPAYLPPED (SEQ ID NO:22)
Smad5	PADTPPPAYMPPDD (SEQ ID NO:23)
Smad2	IPETPPPGYISEDG (SEQ ID NO:24)
Smad3	AGLTPPPGYLSEDG (SEQ ID NO:25)

A detailed evaluation of the interactions of Smad 7 with the WWP1 WW domains and the second WW domain from RSP5 was undertaken. GST was used to correct for nonspecific background interactions. The peptide titration of the WW domains was evaluated by a nonlinear, least squares fit of the data and Scatchard analysis (Figures 8A-8B). Both methods showed that WWP1.2 had very specific interactions with Smad 7 peptide ($K_d = 2.4 \mu\text{M}$). Binding interactions from WWP1.1 and WWP1.3 did not yield a linear plot in the Scatchard analysis.

These results indicate that HECT E3 ubiquitin ligase WW domains bind to Smad protein PY motifs.

Example 3
Coupled Ubiquitin Assay for Detecting HECT E3 Ligase Ubiquitination

This Example illustrates a coupled enzymatic assay that evaluates the fate of a labeled ubiquitin molecule in the E1/E2/E3 pathway.

32

Recombinant E1 (ubc5c) and E2 (ubc7) components were obtained from BostonBiochem (Cambridge, MA). Radiolabeled ubiquitin was generated by PKA-mediated incorporation of [32 P]-phosphate from α -[32 P]-ATP to the PKA site of the GST-Ub fusion protein (pGEX KG expression vector). The ubiquitin assay buffer (UbB) was as follows: 50 mM Tris pH7.6, 1 mM ATP, 0.2 mM EDTA, 5 mM MgCl₂, 1 unit inorganic pyrophosphatase, 0.005% Triton X100, and 1 μ M staurosporine. In a 0.030 mL reaction, the following components were present: 50-200 ng E1, 0.1-1 μ g E2 and 5 μ g GST-Ub. Reactions were run at room temperature and terminated with a SDS-PAGE loading buffer that did not contain mercaptans. Reactions were analyzed by SDS-PAGE. The ubiquitination of active site cysteine residues of E1 and E2s (ubc 5c and ubc 7) was observed (Figures 9A-9C). The addition of 20 mM DTT prevented the formation of the thioester intermediates (Figures 9B-9C).

To evaluate transfer to a HECT E3 ligase, assays were performed as above, with the addition of 50-100 ng of the WWP1 HECT domain containing residues 611-985 or 611-990 of WWP1, as indicated. Sequences of these domains are shown below:

WWP1 HECT domain 611-985:

GFRWKL AHFRYLCQSNALPSHVKINVS RQTLFEDSFQQIMALKPYDLRR
 RLYVIFRGEGLDYGGLAREWFFLLSHEVLNPMYCLFEYAGKNNYCLQI
 NPASTINPDHLSYFCFIGRFIAMALFHGKFIDTGFSLPFYKRMLSKKLTIKD
 LESIDTEFYNSLIWIRDNNIEECGLEMYFSVDMEILGKVTSHDLKLGGSN
 LVTEENKDEYIGLMTEWRFSRGVQEQTKAFLDGFNEVVPLQWLQYFDE
 KELEVMLCGMQEVDLADWQRNTVYRHYTRNSKQIWFVQFVKETDNE
 VRMRLQLQFVTGTCRLPLGGFAELMGSGPRNSQKFCIEKVGKDTWLPRS
 HTCENRLDLPPYKSYEQLKEKLLFAIEETE (SEQ ID NO:31)

WWP1 HECT domain 611-990:

GFRWKL AHFRYLCQSNALPSHVKINVS RQTLFEDSFQQIMALKPYDLRR
 RLYVIFRGEGLDYGGLAREWFFLLSHEVLNPMYCLFEYAGKNNYCLQI
 NPASTINPDHLSYFCFIGRFIAMALFHGKFIDTGFSLPFYKRMLSKKLTIKD
 LESIDTEFYNSLIWIRDNNIEECGLEMYFSVDMEILGKVTSHDLKLGGSN
 LVTEENKDEYIGLMTEWRFSRGVQEQTKAFLDGFNEVVPLQWLQYFDE
 KELEVMLCGMQEVDLADWQRNTVYRHYTRNSKQIWFVQFVKETDNE
 VRMRLQLQFVTGTCRLPLGGFAELMGSGPRNSQKFCIEKVGKDTWLPRS
 HTCENRLDLPPYKSYEQLKEKLLFAIEETEGFGQE (SEQ ID NO:32).

The HECT domain of WWP1 was shown to be charged by either E1/ubc5C or E1/ubc7 (Figures 10A-10C and 11A-11C). The shorter HECT domain, WWP1(611-985), only became charged with one ubiquitin molecule, presumably on its active site cysteine. The sensitivity of the ubiquitin adduct with WWP1(611-985) to DTT is consistent with the bond being to the active site cysteine (Figures 11A and 11B, compare lane 4 to lane 2). The longer HECT domain, WWP1(611-990), displayed a lack of substrate selectivity (Figures 10A and 10B). Time courses of the WWP1(611-990) reactions mediated by either ubc5c or ubc7 indicated that the E2 ubc5c was more efficient at activating WWP1(611-990) (Figures 12A-12C). The loss of GST-ubiquitin correlated with the appearance of high molecular species (>201 kDa).

These results confirm the role of HECT E3 ubiquitin ligases in Smad protein degradation.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for the purpose of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the present invention is not limited except by the appended claims.

Claims

1. A method for screening for an agent that modulates TGF- β - and/or BMP-mediated signaling, comprising the steps of:

(a) contacting

(i) a first polypeptide comprising a HECT E3 ubiquitin ligase WW domain, or a variant thereof in which the ability of the polypeptide to bind to a Smad protein is not substantially diminished relative to the HECT E3 ubiquitin ligase;

(ii) a second polypeptide comprising a Smad PY motif, or a variant thereof in which the ability of the polypeptide to bind to an E3 ubiquitin ligase is not substantially diminished relative to a native Smad protein comprising the PY motif; and

(iii) a candidate agent; under conditions that permit a detectable level of binding of the first polypeptide to the second polypeptide in the absence of candidate agent;

(b) determining a level of binding of the first polypeptide to the second polypeptide; and

(c) comparing the level of binding to a control level of binding of the first polypeptide to the second polypeptide in the absence of candidate agent, and therefrom determining whether the candidate agent modulates TGF- β - and/or BMP-mediated signaling.

2. A method according to claim 1, wherein the HECT E3 ubiquitin ligase WW domain comprises the sequence

GPLPXGWEX₃tttGtXYYhXHNTtTTtWXtPt (SEQ ID NO:2)

wherein each t is an independently selected polar amino acid residue (*e.g.*, S, H, P, D, E, T or Y), h is a hydrophobic residue (*e.g.*, I, V, L or M) and each X is an independently selected amino acid residue.

3. A method according to claim 1, wherein the Smad PY motif comprises the sequence Ser/Thr-Pro-Pro-Pro-Pro/Ala/Gly-Tyr (SEQ ID NO:15), wherein Ser/Thr is an amino acid residue that is serine or threonine and Pro/Ala/Gly is an amino acid residue that is selected from the group consisting of proline, alanine and glycine.

4. A method according to claim 3, wherein the Smad PY motif comprises the sequence TPPPAY (SEQ ID NO:16) or TPPPGY (SEQ ID NO:18).

5. A method according to claim 1, wherein the candidate agent is a small molecule within a combinatorial library.

6. A method according to claim 1, wherein the first polypeptide is immobilized on a solid support and the second polypeptide comprises a tag.

7. A method according to claim 1, wherein the second polypeptide is immobilized on a solid support and the first polypeptide comprises a tag.

8. A method according to claim 6 or claim 7, wherein the tag is biotin or a radioactive group.

9. A method according to claim 1, wherein the level of binding is determined via a two-antibody sandwich assay.

10. A method according to claim 1, wherein the level of binding is determined via a competitive assay.

11. A method for screening for an agent that modulates TGF- β -and/or BMP-mediated signaling, comprising the steps of:

(a) contacting

36

- (i) a candidate agent;
 - (ii) a ubiquitinated HECT E3 ubiquitin ligase; and
 - (iii) a Smad protein or a variant thereof that comprises a PY motif; wherein the contact takes place under conditions and for a time sufficient to permit ubiquitination of the Smad protein or variant thereof by the HECT E3 ubiquitin ligase in the absence of candidate agent;
- (b) determining a level of ubiquitination of the Smad protein or variant thereof; and
 - (c) comparing the level of ubiquitination to a control level of ubiquitination in the absence of candidate agent, and therefrom determining whether the candidate agent modulates TGF- β - and/or BMP-mediated signaling.

12. A method according to claim 11, wherein the method comprises a coupled ubiquitination assay.

13. A method according to claim 11, wherein the ubiquitinated HECT E3 ubiquitin ligase is present within a cell extract fraction.

14. A method according to claim 11, wherein the level of ubiquitination is determined by Western blot analysis.

15. A method according to claim 11, wherein the Smad protein or variant thereof comprises a tag.

16. A method for screening for an agent that modulates BMP-mediated signaling, comprising the steps of:

- (a) contacting a cell that expresses a BMP receptor with a bone morphogenic protein and a candidate agent; and
- (b) detecting a level of a Smad protein in the cell, relative to a level of the Smad protein in a cell that is contacted with the bone morphogenic protein in the

absence of the candidate agent, and therefrom determining whether the candidate agent is a modulator of BMP-mediated signaling.

17. A method according to claim 16, wherein the Smad protein is Smad1 or Smad5.

18. A method according to claim 16, wherein the cell is a bone cell.

19. A method according to claim 16, wherein the cell is a neuron or kidney cell.

20. A method according to claim 16, wherein the agent enhances BMP-mediated signaling.

21. A method for screening for an agent that modulates BMP-mediated signaling, comprising the steps of:

(a) contacting a cell that expresses a BMP receptor with a bone morphogenic protein and a candidate agent; and

(b) detecting a level of ubiquitination of a Smad protein in the cell, relative to a level of the Smad protein ubiquitination in a cell that is contacted with the bone morphogenic protein but is not contacted with the candidate agent, and therefrom determining whether the candidate agent modulates BMP-mediated signaling.

22. A method according to claim 21, wherein the Smad protein is Smad1 or Smad5.

23. A method according to claim 21 wherein the cell is a bone cell.

24. A method according to claim 21, wherein the cell is a neuron or kidney cell.

25. A method according to claim 21, wherein the agent enhances BMP-mediated signaling.

26. A method for screening for an agent that modulates TGF- β -mediated signaling, comprising the steps of:

(a) contacting a cell that expresses a TGF- β receptor with TGF- β and a candidate agent; and

(b) detecting a level of a Smad protein in the cell, relative to a level of the Smad protein in a cell that is contacted with the bone morphogenic protein in the absence of the candidate agent, and therefrom determining whether the candidate agent is a modulator of TGF- β -mediated signaling.

27. A method according to claim 26, wherein the Smad protein is Smad2 or Smad3.

28. A method according to claim 26, wherein the agent enhances TGF- β -mediated signaling.

29. A method for screening for an agent that modulates TGF- β -mediated signaling, comprising the steps of:

(a) contacting a cell that expresses a TGF- β receptor with TGF- β and a candidate agent; and

(b) detecting a level of ubiquitination of a Smad protein in the cell, relative to a level of the Smad protein ubiquitination in a cell that is contacted with the bone morphogenic protein but is not contacted with the candidate agent, and therefrom determining whether the candidate agent modulates TGF- β -mediated signaling.

30. A method according to claim 29, wherein the Smad protein is Smad2 or Smad3.

31. A method according to claim 29, wherein the agent enhances TGF- β -mediated signaling.

32. A method for screening for an agent that modulates BMP-mediated signaling, comprising the steps of:

(a) contacting a cell that expresses a BMP receptor with bone morphogenic protein and a candidate agent; and

(b) detecting a level of a HECT E3 ubiquitin ligase activity in the cell, relative to a level of HECT E3 ubiquitin ligase activity in a cell that is contacted with the bone morphogenic protein in the absence of the candidate agent, and therefrom determining whether the candidate agent modulates BMP-mediated signaling.

33. A method according to claim 32, wherein the cell is a bone cell.

34. A method according to claim 32, wherein the cell is a neuron or kidney cell.

35. A method according to claim 32, wherein the agent enhances BMP-mediated signaling.

36. A method for screening for an agent that modulates TGF- β -mediated signaling, comprising the steps of:

(a) contacting a cell that expresses a TGF- β receptor with TGF- β and a candidate agent; and

(b) detecting a level of a HECT E3 ubiquitin ligase activity in the cell, relative to a level of HECT E3 ubiquitin ligase activity in a cell that is contacted with the bone morphogenic protein in the absence of the candidate agent, and therefrom determining whether the candidate agent modulates TGF- β -mediated signaling.

40

37. A method according to claim 36, wherein the agent enhances TGF- β -mediated signaling.

38. A method for augmenting TGF- β - and/or BMP-mediated signaling in a cell, comprising contacting a cell with an agent that inhibits binding of a HECT E3 ubiquitin ligase WW domain to a Smad PY motif.

39. A method according to claim 38, wherein the Smad PY motif comprises the sequence TPPPAY (SEQ ID NO:16).

40. A method according to claim 38, wherein the Smad PY motif comprises the sequence TPPPGY (SEQ ID NO:18).

41. A method for augmenting TGF- β and/or BMP-mediated signaling in a cell, comprising contacting a cell with an agent that inhibits ubiquitination of a Smad protein.

42. A method according to claim 41, wherein the Smad protein is Smad1 or Smad5.

43. A method according to claim 41, wherein the Smad protein is Smad2 or Smad3.

44. A method for stimulating bone formation in a patient, comprising administering to a patient a therapeutically effective amount of an agent that inhibits binding of a HECT E3 ubiquitin ligase WW domain to a Smad PY motif.

45. A method according to claim 44, wherein the Smad PY motif comprises the sequence TPPPAY (SEQ ID NO:16).

41

46. A method for stimulating bone formation in a patient, comprising administering to a patient a therapeutically effective amount of an agent that inhibits ubiquitination of a Smad protein.
47. A method according to claim 46, wherein the Smad protein is Smad1 or Smad5.
48. A method for preventing or treating a condition associated with insufficient TGF- β and/or BMP-mediated cell signaling, comprising administering to a patient a therapeutically effective amount of an agent that inhibits binding of a HECT E3 ubiquitin ligase WW domain to a Smad PY motif.
49. A method according to claim 48, wherein the Smad PY motif comprises the sequence TPPPAY (SEQ ID NO:16).
50. A method according to claim 48, wherein the Smad PY motif comprises the sequence TPPPGY (SEQ ID NO:17).
51. A method for preventing or treating a condition associated with insufficient TGF- β and/or BMP-mediated cell signaling, comprising administering to a patient a therapeutically effective amount of an agent that inhibits ubiquitination of a Smad protein.
52. A method according to claim 51, wherein the Smad protein is Smad1 or Smad5.
53. A method according to claim 51, wherein the Smad protein is Smad2 or Smad3.

42

54. A method according to claim 48 or claim 51, wherein the condition is a cancer or inflammation.

1/15




Fig. 1

2/15




Fig. 2

BMP
LLF

3/15




Fig. 3

4/15








Fig. 4



5/15

*Fig. 5A**Fig. 5B*



6/15

*Fig. 5C**Fig. 5D*



7/15

*Fig. 6A**Fig. 6B*

8/15

*Fig. 6C**Fig. 6D*

9/15

*Fig. 7A**Fig. 7B*





Fig. 8A

11/15

*Fig. 8B*

12/15




Fig. 9C

Fig. 9B

Fig. 9A

13/15




Fig. 10C

Fig. 10B

Fig. 10A

14/15




Fig. 11C

Fig. 11B

Fig. 11A

15/15




Fig. 12C

Fig. 12B

Fig. 12A

SEQUENCE LISTING

<110> Signal Pharmaceuticals, Inc.
Heokstra, Merl F.
Xie, Weilin
Murray, Brion
Mercurio, Frank

<120> METHODS FOR MODULATING SIGNAL
TRANSDUCTION MEDIATED BY TGF-BETA AND RELATED PROTEINS

<130> 860098.433PC

<140> PCT

<141> 2000-08-29

<160> 32

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 108

<212> PRT

<213> Homo sapien

<220>

<221> VARIANT

<222> (1)...(1)

<223> Xaa = Tyrosine or Phenylalanine

<221> VARIANT

<222> (2)...(4)

<223> Xaa = any amino acid; 0-1 residues may be missing

<221> VARIANT

<222> (6)...(16)

<223> Xaa = any amino acid; 0-3 residues may be missing

<221> VARIANT

<222> (20)...(20)

<223> Xaa = any amino acid

<221> VARIANT

<222> (22)...(22)

<223> Xaa = Valine, Isoleucine or Leucine

<221> VARIANT

<222> (23)...(27)

<223> Xaa = any amino acid

<221> VARIANT

<222> (29)...(29)

<223> Xaa = any amino acid

<221> VARIANT

<222> (30)...(30)

<223> Xaa = Lysine or Arginine

<221> VARIANT

<222> (31)...(33)

<223> Xaa = any amino acid

<221> VARIANT

<222> (34)...(34)

<223> Xaa = Leucine or Valine

<221> VARIANT

<222> (37)...(37)

<223> Xaa = Valine or Leucine

<221> VARIANT

<222> (40)...(40)

<223> Xaa = Threonine or Serine

<221> VARIANT

<222> (41)...(41)

<223> Xaa = any amino acid

<221> VARIANT

<222> (45)...(45)

<223> Xaa = Leucine, Valine, Methionine, Alanine or Isoleucine

<221> VARIANT

<222> (46)...(46)

<223> Xaa = any amino acid

<221> VARIANT

<222> (49)...(50)

<223> Xaa = any amino acid

<221> VARIANT

<222> (52)...(61)

<223> Xaa = any amino acid; 0-6 residues may be missing

<221> VARIANT

<222> (63)...(71)

<223> Xaa = any amino acid; 0-2 residues may be missing

<221> VARIANT

<222> (74)...(75)

<223> Xaa = any amino acid

<221> VARIANT

<222> (81)...(81)

<223> Xaa = any amino acid

<221> VARIANT
 <222> (86)...(86)
 <223> Xaa = any amino acid

<221> VARIANT
 <222> (88)...(88)
 <223> Xaa = any amino acid

<221> VARIANT
 <222> (90)...(92)
 <223> Xaa = any amino acid

<221> VARIANT
 <222> (93)...(93)
 <223> Xaa = Leucine or Methionine

<221> VARIANT
 <222> (94)...(95)
 <223> Xaa = any amino acid

<221> VARIANT
 <222> (96)...(96)
 <223> Xaa = Arginine or Lysine

<221> VARIANT
 <222> (98)...(99)
 <223> Xaa = any amino acid

<221> VARIANT
 <222> (102)...(107)
 <223> Xaa = any amino acid; 0-2 residues may be missing

<400> 1
 Xaa Xaa Xaa Xaa Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1 5 10 15
 Trp Phe Trp Xaa Ile Xaa Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa
 20 25 30
 Xaa Xaa Gln Phe Xaa Thr Gly Xaa Xaa Arg Leu Pro Xaa Xaa Gly Phe
 35 40 45
 Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ile Xaa Xaa
 50 55 60
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Pro Xaa Xaa His Thr Cys Phe Asn
 65 70 75 80
 Xaa Leu Asp Leu Pro Xaa Tyr Xaa Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 85 90 95
 Leu Xaa Xaa Ala Ile Xaa Xaa Xaa Xaa Xaa Xaa Phe
 100 105

<210> 2
 <211> 33
 <212> PRT
 <213> Homo sapien

<220>
 <221> VARIANT

<222> (5)...(5)
<223> Xaa = any amino acid

<221> VARIANT
<222> (9)...(11)
<223> Xaa = any amino acid

<221> VARIANT
<222> (12)...(14)
<223> Xaa = independently selected polar amino acid
(e.g., S,H,P,D,E,T or Y)

<221> VARIANT
<222> (16)...(16)
<223> Xaa = independently selected polar amino acid
(e.g., S,H,P,D,E,T or Y)

<221> VARIANT
<222> (17)...(17)
<223> Xaa = any amino acid

<221> VARIANT
<222> (20)...(20)
<223> Xaa = hydrophobic residue (e.g., I,V,L or M)

<221> VARIANT
<222> (21)...(21)
<223> Xaa = any amino acid

<221> VARIANT
<222> (25)...(25)
<223> Xaa = independently selected polar amino acid
(e.g., S,H,P,D,E,T or Y)

<221> VARIANT
<222> (28)...(28)
<223> Xaa = independently selected polar amino acid
(e.g., S,H,P,D,E,T or Y)

<221> VARIANT
<222> (30)...(30)
<223> Xaa = any amino acid

<221> VARIANT
<222> (31)...(31)
<223> Xaa = independently selected polar amino acid
(e.g., S,H,P,D,E,T or Y)

<221> VARIANT
<222> (33)...(33)
<223> Xaa = independently selected polar amino acid
(e.g., S,H,P,D,E,T or Y)

<400> 2

Gly Pro Leu Pro Xaa Gly Trp Glu Xaa Xaa Xaa Xaa Xaa Gly Xaa

```

      1             5             10             15
Xaa Tyr Tyr Xaa Xaa His Asn Thr Xaa Thr Thr Xaa Trp Xaa Xaa Pro
      20             25             30
Xaa

```

```

<210> 3
<211> 38
<212> PRT
<213> Homo sapien

```

```

      <400> 3
Ser Pro Leu Pro Pro Gly Trp Glu Glu Arg Gln Asp Ile Leu Gly Arg
      1             5             10             15
Thr Tyr Tyr Val Asn His Glu Ser Arg Arg Thr Gln Trp Lys Arg Pro
      20             25             30
Thr Pro Gln Asp Asn Leu
      35

```

```

<210> 4
<211> 38
<212> PRT
<213> Homo sapien

```

```

      <400> 4
Ser Gly Leu Pro Pro Gly Trp Glu Glu Arg Gln Asp Ile Leu Gly Arg
      1             5             10             15
Thr Tyr Tyr Val Asn His Glu Ser Arg Arg Thr Gln Trp Lys Arg Pro
      20             25             30
Thr Pro Gln Asp Asn Leu
      35

```

```

<210> 5
<211> 38
<212> PRT
<213> Homo sapien

```

```

      <400> 5
Gly Phe Leu Pro Lys Gly Trp Glu Val Arg His Ala Pro Asn Gly Arg
      1             5             10             15
Pro Phe Phe Ile Asp His Asn Thr Lys Thr Thr Thr Trp Glu Asp Pro
      20             25             30
Arg Leu Lys Ile Pro Ala
      35

```

```

<210> 6
<211> 38
<212> PRT
<213> Homo sapien

```

```

      <400> 6
Gly Pro Leu Pro Pro Gly Trp Glu Glu Arg Thr His Thr Asp Gly Arg
      1             5             10             15
Ile Phe Tyr Ile Asn His Asn Ile Lys Arg Thr Gln Trp Glu Asp Pro
      20             25             30

```


Arg Leu Glu Asn Val Ala
35

<210> 7
<211> 38
<212> PRT
<213> *Saccharomyces cerevisiae*

<400> 7
Gly Arg Leu Pro Pro Gly Trp Glu Arg Arg Thr Asp Asn Phe Gly Arg
1 5 10 15
Thr Tyr Tyr Val Asp His Asn Thr Arg Thr Thr Thr Trp Lys Arg Pro
20 25 30
Thr Leu Asp Gln Thr Glu
35

<210> 8
<211> 38
<212> PRT
<213> *Saccharomyces cerevisiae*

<400> 8
Gly Glu Leu Pro Ser Gly Trp Glu Gln Arg Phe Thr Pro Glu Gly Arg
1 5 10 15
Ala Tyr Phe Val Asp His Asn Thr Arg Thr Thr Thr Trp Val Asp Pro
20 25 30
Arg Arg Gln Gln Tyr Ile
35

<210> 9
<211> 38
<212> PRT
<213> *Saccharomyces cerevisiae*

<400> 9
Gly Pro Leu Pro Ser Gly Trp Glu Met Arg Leu Thr Asn Thr Ala Arg
1 5 10 15
Val Tyr Phe Val Asp His Asn Thr Lys Thr Thr Thr Trp Asp Asp Pro
20 25 30
Arg Leu Pro Ser Ser Leu
35

<210> 10
<211> 38
<212> PRT
<213> *Homo sapien*

<400> 10
Leu Pro Ser Gly Trp Gly Trp Glu Gln Arg Lys Asp Pro His Gly Arg
1 5 10 15
Thr Tyr Tyr Val Asp His Asn Thr Arg Thr Thr Thr Trp Glu Arg Pro
20 25 30
Gln Pro Leu Pro Pro Gly
35

<210> 11
 <211> 38
 <212> PRT
 <213> Homo sapien

<400> 11
 Gln Pro Leu Pro Pro Gly Trp Glu Arg Arg Val Asp Asp Arg Arg Arg
 1 5 10 15
 Val Tyr Tyr Val Asp His Asn Thr Arg Thr Thr Thr Trp Gln Arg Pro
 20 25 30
 Thr Met Glu Ser Val Arg
 35

<210> 12
 <211> 38
 <212> PRT
 <213> Homo sapien

<400> 12
 Gly Pro Leu Pro Pro Gly Trp Glu Lys Arg Val Asp Ser Thr Asp Arg
 1 5 10 15
 Val Tyr Phe Val Asn His Asn Thr Lys Thr Thr Gln Trp Glu Asp Pro
 20 25 30
 Arg Thr Gln Gly Leu Gln
 35

<210> 13
 <211> 38
 <212> PRT
 <213> Homo sapien

<400> 13
 Glu Pro Leu Pro Glu Gly Trp Glu Ile Arg Tyr Thr Arg Glu Gly Val
 1 5 10 15
 Arg Tyr Phe Val Asp His Asn Thr Arg Thr Thr Thr Phe Lys Asp Pro
 20 25 30
 Arg Asn Gly Lys Ser Ser
 35

<210> 14
 <211> 4
 <212> PRT
 <213> Homo sapien

<220>
 <221> VARIANT
 <222> (3)...(3)
 <223> Xaa = any amino acid

<400> 14
 Pro Pro Xaa Tyr
 1

<210> 15
 <211> 6

<212> PRT
 <213> Homo sapien

<220>
 <221> VARIANT
 <222> (1)...(1)
 <223> Xaa = Serine or Threonine

<221> VARIANT
 <222> (5)...(5)
 <223> Xaa = Proline, Alanine or Glycine

<400> 15
 Xaa Pro Pro Pro Xaa Tyr
 1 5

<210> 16
 <211> 6
 <212> PRT
 <213> Homo sapien

<400> 16
 Thr Pro Pro Pro Ala Tyr
 1 5

<210> 17
 <211> 14
 <212> PRT
 <213> Homo sapien

<220>
 <221> VARIANT
 <222> (10)...(10)
 <223> Xaa = Leucine or Methionine

<400> 17
 Pro Ala Asp Thr Pro Pro Pro Ala Tyr Xaa Pro Pro Pro Asp
 1 5 10

<210> 18
 <211> 6
 <212> PRT
 <213> Homo sapien

<400> 18
 Thr Pro Pro Pro Gly Tyr
 1 5

<210> 19
 <211> 11
 <212> PRT
 <213> Homo sapien

<220>
 <221> VARIANT

<222> (7)...(7)

<223> Xaa = Isoleucine or Leucine

<400> 19

Thr Pro Pro Pro Gly Tyr Xaa Ser Glu Asp Gly
1 5 10

<210> 20

<211> 14

<212> PRT

<213> Homo sapien

<400> 20

Glu Leu Glu Ser Pro Pro Pro Pro Tyr Ser Arg Tyr Pro Met
1 5 10

<210> 21

<211> 14

<212> PRT

<213> Homo sapien

<400> 21

Gly Pro Glu Ser Pro Pro Pro Pro Tyr Ser Arg Leu Ser Pro
1 5 10

<210> 22

<211> 14

<212> PRT

<213> Homo sapien

<400> 22

Pro Ala Asp Thr Pro Pro Pro Ala Tyr Leu Pro Pro Glu Asp
1 5 10

<210> 23

<211> 14

<212> PRT

<213> Homo sapien

<400> 23

Pro Ala Asp Thr Pro Pro Pro Ala Tyr Met Pro Pro Asp Asp
1 5 10

<210> 24

<211> 14

<212> PRT

<213> Homo sapien

<400> 24

Ile Pro Glu Thr Pro Pro Pro Gly Tyr Ile Ser Glu Asp Gly
1 5 10

<210> 25

<211> 14

<212> PRT

<213> Homo sapien

<400> 25

Ala Gly Leu Thr Pro Pro Pro Gly Tyr Leu Ser Glu Asp Gly
1 5 10

<210> 26

<211> 38

<212> PRT

<213> Homo sapien

<400> 26

Leu Pro Ser Gly Trp Glu Gln Arg Lys Asp Pro His Gly Arg Thr Tyr
1 5 10 15
Tyr Val Asp His Asn Thr Arg Thr Thr Thr Trp Glu Arg Pro Gln Pro
20 25 30
Leu Pro Pro Gly Trp Glu
35

<210> 27

<211> 14

<212> PRT

<213> Homo sapien

<400> 27

Pro Ala Asp Thr Pro Pro Pro Ala His Leu Pro Pro Glu Asp
1 5 10

<210> 28

<211> 14

<212> PRT

<213> Homo sapien

<400> 28

His Pro Gly Thr Pro Pro Pro Pro Tyr Thr Val Gly Pro Gly
1 5 10

<210> 29

<211> 14

<212> PRT

<213> Homo sapien

<400> 29

Ile Pro Gly Thr Pro Pro Pro Asn Tyr Asp Ser Leu Arg Leu
1 5 10

<210> 30

<211> 14

<212> PRT

<213> Homo sapien

<400> 30

Ile Pro Gly Thr Pro Pro Pro Asn His Asp Ser Leu Arg Leu
1 5 10

<210> 31
 <211> 375
 <212> PRT
 <213> Homo sapien

<400> 31
 Gly Phe Arg Trp Lys Leu Ala His Phe Arg Tyr Leu Cys Gln Ser Asn
 1 5 10 15
 Ala Leu Pro Ser His Val Lys Ile Asn Val Ser Arg Gln Thr Leu Phe
 20 25 30
 Glu Asp Ser Phe Gln Gln Ile Met Ala Leu Lys Pro Tyr Asp Leu Arg
 35 40 45
 Arg Arg Leu Tyr Val Ile Phe Arg Gly Glu Glu Gly Leu Asp Tyr Gly
 50 55 60
 Gly Leu Ala Arg Glu Trp Phe Phe Leu Leu Ser His Glu Val Leu Asn
 65 70 75 80
 Pro Met Tyr Cys Leu Phe Glu Tyr Ala Gly Lys Asn Asn Tyr Cys Leu
 85 90 95
 Gln Ile Asn Pro Ala Ser Thr Ile Asn Pro Asp His Leu Ser Tyr Phe
 100 105 110
 Cys Phe Ile Gly Arg Phe Ile Ala Met Ala Leu Phe His Gly Lys Phe
 115 120 125
 Ile Asp Thr Gly Phe Ser Leu Pro Phe Tyr Lys Arg Met Leu Ser Lys
 130 135 140
 Lys Leu Thr Ile Lys Asp Leu Glu Ser Ile Asp Thr Glu Phe Tyr Asn
 145 150 155 160
 Ser Leu Ile Trp Ile Arg Asp Asn Asn Ile Glu Glu Cys Gly Leu Glu
 165 170 175
 Met Tyr Phe Ser Val Asp Met Glu Ile Leu Gly Lys Val Thr Ser His
 180 185 190
 Asp Leu Lys Leu Gly Gly Ser Asn Ile Leu Val Thr Glu Glu Asn Lys
 195 200 205
 Asp Glu Tyr Ile Gly Leu Met Thr Glu Trp Arg Phe Ser Arg Gly Val
 210 215 220
 Gln Glu Gln Thr Lys Ala Phe Leu Asp Gly Phe Asn Glu Val Val Pro
 225 230 235 240
 Leu Gln Trp Leu Gln Tyr Phe Asp Glu Lys Glu Leu Glu Val Met Leu
 245 250 255
 Cys Gly Met Gln Glu Val Asp Leu Ala Asp Trp Gln Arg Asn Thr Val
 260 265 270
 Tyr Arg His Tyr Thr Arg Asn Ser Lys Gln Ile Ile Trp Phe Trp Gln
 275 280 285
 Phe Val Lys Glu Thr Asp Asn Glu Val Arg Met Arg Leu Leu Gln Phe
 290 295 300
 Val Thr Gly Thr Cys Arg Leu Pro Leu Gly Gly Phe Ala Glu Leu Met
 305 310 315 320
 Gly Ser Asn Gly Pro Arg Asn Ser Gln Lys Phe Cys Ile Glu Lys Val
 325 330 335
 Gly Lys Asp Thr Trp Leu Pro Arg Ser His Thr Cys Phe Asn Arg Leu
 340 345 350
 Asp Leu Pro Pro Tyr Lys Ser Tyr Glu Gln Leu Lys Glu Lys Leu Leu
 355 360 365
 Phe Ala Ile Glu Glu Thr Glu
 370 375

<210> 32
 <211> 380
 <212> PRT
 <213> Homo sapien

<400> 32
 Gly Phe Arg Trp Lys Leu Ala His Phe Arg Tyr Leu Cys Gln Ser Asn
 1 5 10 15
 Ala Leu Pro Ser His Val Lys Ile Asn Val Ser Arg Gln Thr Leu Phe
 20 25 30
 Glu Asp Ser Phe Gln Gln Ile Met Ala Leu Lys Pro Tyr Asp Leu Arg
 35 40 45
 Arg Arg Leu Tyr Val Ile Phe Arg Gly Glu Glu Gly Leu Asp Tyr Gly
 50 55 60
 Gly Leu Ala Arg Glu Trp Phe Phe Leu Leu Ser His Glu Val Leu Asn
 65 70 75 80
 Pro Met Tyr Cys Leu Phe Glu Tyr Ala Gly Lys Asn Asn Tyr Cys Leu
 85 90 95
 Gln Ile Asn Pro Ala Ser Thr Ile Asn Pro Asp His Leu Ser Tyr Phe
 100 105 110
 Cys Phe Ile Gly Arg Phe Ile Ala Met Ala Leu Phe His Gly Lys Phe
 115 120 125
 Ile Asp Thr Gly Phe Ser Leu Pro Phe Tyr Lys Arg Met Leu Ser Lys
 130 135 140
 Lys Leu Thr Ile Lys Asp Leu Glu Ser Ile Asp Thr Glu Phe Tyr Asn
 145 150 155 160
 Ser Leu Ile Trp Ile Arg Asp Asn Asn Ile Glu Glu Cys Gly Leu Glu
 165 170 175
 Met Tyr Phe Ser Val Asp Met Glu Ile Leu Gly Lys Val Thr Ser His
 180 185 190
 Asp Leu Lys Leu Gly Gly Ser Asn Ile Leu Val Thr Glu Glu Asn Lys
 195 200 205
 Asp Glu Tyr Ile Gly Leu Met Thr Glu Trp Arg Phe Ser Arg Gly Val
 210 215 220
 Gln Glu Gln Thr Lys Ala Phe Leu Asp Gly Phe Asn Glu Val Val Pro
 225 230 235 240
 Leu Gln Trp Leu Gln Tyr Phe Asp Glu Lys Glu Leu Glu Val Met Leu
 245 250 255
 Cys Gly Met Gln Glu Val Asp Leu Ala Asp Trp Gln Arg Asn Thr Val
 260 265 270
 Tyr Arg His Tyr Thr Arg Asn Ser Lys Gln Ile Ile Trp Phe Trp Gln
 275 280 285
 Phe Val Lys Glu Thr Asp Asn Glu Val Arg Met Arg Leu Leu Gln Phe
 290 295 300
 Val Thr Gly Thr Cys Arg Leu Pro Leu Gly Gly Phe Ala Glu Leu Met
 305 310 315 320
 Gly Ser Asn Gly Pro Arg Asn Ser Gln Lys Phe Cys Ile Glu Lys Val
 325 330 335
 Gly Lys Asp Thr Trp Leu Pro Arg Ser His Thr Cys Phe Asn Arg Leu
 340 345 350
 Asp Leu Pro Pro Tyr Lys Ser Tyr Glu Gln Leu Lys Glu Lys Leu Leu
 355 360 365
 Phe Ala Ile Glu Glu Thr Glu Gly Phe Gly Gln Glu
 370 375 380

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/23729

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 G01N33/68 C12Q1/25 G01N33/50 G01N33/566		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 G01N C12Q		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) BIOSIS, MEDLINE, EPO-Internal, WPI Data, PAJ		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ZHU HAITAO ET AL: "A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation." NATURE (LONDON), vol. 400, no. 6745, 12 August 1999 (1999-08-12), pages 687-693, XP000960653 ISSN: 0028-0836 page 688, right-hand column, paragraph 2 page 688, right-hand column, paragraph 5 ---	1-15
A	WO 99 01765 A (SLOAN KETTERING INST CANCER) 14 January 1999 (1999-01-14) the whole document --- ---	1-54
-/--		
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
* Special categories of cited documents:		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*8* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center;">11 December 2000</div>		Date of mailing of the international search report <div style="text-align: center;">18/12/2000</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center;">Gundlach, B</div>

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/23729

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MIYAZONO K: "Signal transduction by bone morphogenetic protein receptors: Functional roles of Smad proteins." BONE (NEW YORK), vol. 25, no. 1, July 1999 (1999-07), pages 91-93, XP000964877</p> <p>Second Joint Meeting of the American Society for Bone and Mineral Research and the International Bone and Mineral Society; San Francisco, California, USA; December 1-6, 1998</p> <p>ISSN: 8756-3282</p> <p>the whole document</p> <p>---</p>	1-54
A	<p>HELDIN ET AL: "TGF-beta signalling from cell membrane to nucleus through SMAD proteins" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 390, 4 December 1997 (1997-12-04), pages 465-471, XP002110963</p> <p>ISSN: 0028-0836</p> <p>the whole document</p> <p>-----</p>	1-54

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 44-54 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/US 00/23729

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9901765 A	14-01-1999	AU 8281398 A	25-01-1999

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.